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ABSTRACT 
Objective: Sitagliptin phosphate and metformin hydrochloride tablet is an FDA approved combination product for the treatment of diabetes 
mellitus type 2. There are no reported evidence for estimation of undesired (S)-sitagliptin in a combination product. The objective of this study was 
to develop a high sensitive liquid chromatography method for the determination of (S)-enantiomer of sitagliptin phosphate in a fixed dose 
combination formula of metformin and sitagliptin. 
Methods: The proposed novel high-performance liquid chromatography (HPLC) method uses programmed gradient elution of a mixture of ethanol-
diethylamine(DEA) 100:0.1 (v/v) as mobile phase-A and a mixture of methanol-water 60:40 (v/v) as mobile phase-B. The chromatographic 
conditions were designed to nullify the metformin interference and in which sitagliptin enantiomers elute first and followed by metformin. A 
satisfactory resolution (≥2.5) between (S) -sitagliptin and active form (R)-sitagliptin was achieved with gradient elution on Chiralpak IA column 
(5μm, 4 × 250 mm) at a flow rate of 0.5 ml/min and the detector wavelength set at 265 nm. The injection volume set as 10 µl. The developed method 
has been validated as per the International Conference on Harmonisation (ICH) guidelines. 
Results: The proposed HPLC method for determination of (S)-sitagliptin, showed good linearity in the concentration range of 0.5 µg/ml to 13.6 
µg/ml and capable to quantify accurately up to the lowest level (LOQ) of 0.017%. The validated method was successfully applied to quantify the (S)-
sitagliptin for different marketed formulations of sitagliptin with metformin and sitagliptin alone, and the corresponding recovery values were 
found to be in the range of 95.1% to 98.4%. 
Conclusion: The proposed validated HPLC method was found to be suitable for the quantitative determination of (S)-sitagliptin in the formulations 
of sitagliptin with metformin and sitagliptin alone. 
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Sitagliptin phosphate (SIT) is chemically 7-[(3R)-3-amino-1-oxo-4-
(2,4,5 trifluorophenyl) butyl]-5,6,7,8-tetrahydo-3-(trifluoromethyl)-
1,2,4-Triazolo [4,3-a] pyrazine phosphate (1:1) monohydrate (fig. 1). 
SIT is used for the improvement of glycemic control among patients 
with type II diabetes mellitus, either as monotherapy or as 
combination therapy with metformin hydrochloride (MET) when 
the single agent does not provide adequate glycemic control [1-2]. 
The combination of sitagliptin phosphate and metformin 
hydrochloride proved to be effective in controlling the metabolic 
syndrome and resulted in significant weight loss, the reversal of 
insulin resistance is let and adipocyte hypertrophy and alleviated 
hepatic steatosis [3]. Merck markets SIT in combination with MET in 
a single dosage form, brand name as Janumet. In Janumet these 
drugs are available in 50/500 mg and 50/1000 mg of SIT and MET, 
respectively.  
During the synthesis of sitagliptin, there is a possibility of carrying 
an undesired (S)-enantiomer of enantiopure sitagliptin, therefore 
the enantioselective analytical method is necessary to ensure its 
therapeutic efficacy and safety. The development of analytical 
methods for the assessment of enantiomeric purity is challenging 
due to the fact that enantiomers possess virtually identical 
properties [4]. However, no methods have been reported for 
quantification of undesired (S)-enantiomer of sitagliptin in a 
combination formula of SIT and MET. For drug products, it should be 
confirmed that the eutomer is present in the required dose while the 
distomer level should be analyzed as an impurity, as prescribed in 
the guidelines imposed by the International Conference on 
Harmonization (ICH), more precisely in guideline Q6A (decision tree 
number 5) [5]. But literature survey reveals that there are analytical 
methods available for determination of (S)-enantiomer of sitagliptin 
in bulk drug and formulation samples of sitagliptin phosphate using 
chiral stationary phases by HPLC [6-7]. The reported chiral 
chromatographic methods were not suitable for estimation of (S)-
enantiomer of sitagliptin in combination drug product of sitagliptin 
and metformin. Few methods have been reported only for 
estimation of SIT and metal one and in combination [8, 9-20, 21]. 
The combination product Janumet contains a high content of 
metformin i.e. 1000 mg for 50 mg of sitagliptin. Therefore, it is 
challenge to develop a sensitive and high-throughput assay for 
quantification of sitagliptin enantiomers in the presence of 
metformin. Optimization of sample preparation and 
chromatographic conditions are needed to avoid metformin 
interference in chromatography. The aim of the present article 
describes the quantitative determination of (S)-enantiomer of 
sitagliptin phosphate in a combination dosage of SIT and MET by 
using reverse phase chromatography. In continuation of our 
research work for determination of impurities in pharmaceutical 
dosage forms [22-23], the present communication forms the first 
report of a simple, sensitive and reproducible method for 
determination of (S)-enantiomer of sitagliptin phosphate in 
combination product of SIT and MET. 
MATERIALS AND METHODS 
Chemicals 
Sitagliptin and its (S)-enantiomer (fig. 1) were provided by Auro 
pharma, Hyderabad, India. Metformin was provided by Granules, 
India. Commercially available Janumet (immediate release) and 
Janumet XR (extended release) tablets nominally containing 64.25 
mg of sitagliptin phosphate monohydrate and 1000 mg of metformin 
were purchased at a local drugstore. HPLC grade methanol, ethanol, 
and diethylamine were purchased from Merck, Germany. 
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Fig. 1: Chemical structures of (A) sitagliptin and (B) (S)-enantiomer of sitagliptin 
 
Equipment 
The system used for method development and validation study was 
Agilent HPLC 1200 series (Agilent technologies, Germany) with 
Ezchrom elite software equipped with G1322A degasser, G1311A 
quaternary pump, G1315C auto-injector, G16A column oven and 
G1315C DAD detector. 
Chromatographic conditions 
The chromatographic conditions were optimized using a 
polysaccharide derivative immobilized on silica particles as chiral 
stationary phase Chiralpak IA (250 x 4.6 mm, 5 µm, Daicel make) 
which was safeguarded with a 1 cm long guard column. The mobile 
phase-A contains ethanol with 0.1% of diethylamine and mobile 
phase-B contains a mixture of methanol-water 60:40 (v/v). The flow 
rate was 0.5 ml/min. The developed gradient program was: 0.01 
min–0% B, 18.0 min–0% B, 22.0 min–100% B, 48.0 min–100% B, 
52.0 min–0% B and 78.0 min–0% B. The detection was carried out at 
a wavelength of 265 nm. The injection volume was 10 µl. The 
column and sample compartment temperature was maintained at 25 
°C. The developed conditions in an isocratic mode using mobile 
phase-A with a run time 20 min can also be used for sitagliptin bulk 
drug and formulations for monitoring of (S)-sitagliptin. All 
calculations concerning the quantitative analysis were performed 
with external standardization by measurement of peak areas. 
System suitability solution 
A stock solution of (S)-enantiomer (0.015 mg/ml) and sitagliptin 
phosphate (0.015 mg/ml) were prepared by dissolving the appropriate 
amount of the substances in ethanol and diluted the solution to get 
concentration 4.5 µg/ml was used as system suitability solution.  
Sample preparation 
The samples were prepared by weighing about 300 mg of sitagliptin 
phosphate equivalent Janumet tablet powder into 100-ml flask and 
dissolving in ethanol by sonication to get 3.0 mg/ml concentration of 
sitagliptin phosphate. Addition of 2 ml of water to each preparation 
was done, before proceeding for sonication. Sample solutions were 
filtered through 0.45 µm syringe filter before injecting into HPLC. 
Method validation 
The developed liquid chromatographic method for quantification of 
(S)-enantiomer of sitagliptin in formulated samples was validated 
according to ICH Guidelines [25-26]. As a part of the validation 
study, the method was evaluated for parameters mentioned in 
guidelines like system suitability, specificity, precision, linearity, the 
limit of detection, the limit of quantification, recovery studies, 
solution stability and robustness of chromatographic conditions. 
RESULTS AND DISCUSSION 
Method development 
Method development was initiated using marketed formulation 
Janumet tablets 50/1000 mg strength. Optimization of 
chromatographic conditions and sample preparation experiments 
were carried a parallel but we noticed, it is impractical to optimize 
chromatographic conditions for low-level quantification of (S)-
enantiomer in the presence of completely dissolved metformin, 
hence sample preparation optimization trails were taken initially 
followed by optimization of chromatographic conditions. 
Sample preparation optimization 
Sample preparation is an important step in the pharmaceutical 
analysis to control matrix effects and to improve the sensitivity as 
well as to achieve better analyte recovery. A minimum of 3.0 
mg/ml of sitagliptin phosphate solution required to get optimum 
sensitivity for (S)-enantiomer (≤0.05%) [24] relative to its 
eutomer. If the metformin completely dissolved in a chosen 
diluent, the sample with 3.0 mg/ml of sitagliptin of Janumet 
50/1000 mg solution contains about 46.6 mg/ml of metformin. 
The matrix metformin effect is a major concern and needs to be 
minimized by choosing a solvent in which the metformin solubility 
is less and sitagliptin phosphate is fully soluble. Different solvent 
systems from non-polar to polar were practically inquired in 
which metformin partially soluble or insoluble and whereas 
sitagliptin phosphate having more solubility. Dramatically in most 
of the solvents both metformin and sitagliptin phosphate were 
exhibited similar kind of solubility. But only in ethanol and 
dimethyl sulphoxide, the solubility of metformin is<6 mg/ml and 
sitagliptin phosphate is fully soluble. Out of these two solvents, 
ethanol as a diluent was chosen to get good compatibility with 
chiral stationary phases. The (S)-enantiomer of sitagliptin 
phosphate recovery was good when the tablet powder was in 
contact with at least 2 ml of water before addition of ethanol 
during sample preparation. Sonication of about 30 min is 
necessary for effective extraction of (S)-enantiomer from tablet 
powder.  
Chromatographic conditions optimization 
Optimization trails for chromatographic conditions can be 
minimized by effective sample preparation i.e. by minimizing the 
matrix effects. Metformin matrix effect was minimized by choosing 
ethanol as diluent. The reported literature methods of reverse phase 
and normal phase were evaluated by injecting metformin solution 
and in which metformin is eluting as flat peak and have no 
separation with sitagliptin. To develop a rugged and suitable liquid 
chromatography method for the separation of sitagliptin 
enantiomers in the presence of MET, different mobile phases and 
stationary phases were employed. To achieve the chromatographic 
separation, various chiral columns like Chiralcel ODH, Chiralpak AS-
H, Lux Amylose 2, Daicel Chiralpak AD 3 and Whelk-O-1 (Merck) 
were used. Various experiments were conducted, to select the best 
stationary and mobile phases that would give optimum resolution 
and selectivity of the enantiomers and separation with metformin. 
Poor separation of enantiomers with metformin was found on 
Chiralcel OD-H, Whelk-O-1 and Chiralpak AS-H columns using 
different possible mobile phases with normal phase conditions. 
Metformin logP
Various trials with ethanol, different ratios of ethanol-water and 
different ratios of methanol-water as mobile phases were used in 
our initial efforts in the reverse phase separation. The trials were 
made initially in isocratic mode using Chiral IA, IB and IC columns. In 
isocratic mode, sitagliptin isomers separation is less than 2.0 and the 
elution of metformin is occurring even after 100 min of runtime, 
may be due to insufficient elution strength of mobile phase. Hence 
gradient elution was designed in such a way that, to elute sitagliptin 
 value is very low indicating its polar nature and is 
sparingly soluble in non-polar solvents, hence elution with normal 
phase chromatography was not suitable and reverse phase 
chromatography is the only option to wash out a high concentration 
of metformin in the sample solution.  
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enantiomers within 20 min and followed by elution of metformin. 
There is an indication of separation of metformin with sitagliptin 
enantiomers in gradient mode on Chiralpak IA column using a 0.1% 
diethylamine in ethanol as mobile phase-A and methanol-water 
60:40 (v/v) as mobile phase-B at 0.7 ml/min flow rate. The decrease 
in flow from 0.7 ml/min to 0.5 ml/min further increased the 
resolution between sitagliptin enantiomers. The optimized final 
conditions with Chiralpak IA were given in section-Chromatographic 
conditions. The chromatogram was monitored at wavelength 265 
nm. The resolution between enantiomers was found to be greater 
than 2.0 and no interference observed from metformin. In the 
optimized method, the typical retention time of (S)-enantiomer, 
sitagliptin and metformin were about 13.6, 15.7 and 51.1 min 
respectively. The chromatogram of a mixture of sitagliptin 
enantiomers alone and (S)-enantiomer of sitagliptin spiked with 
tablet sample are displayed in fig. 2C and 3A.  
Analysis of formulated samples 
Analyzed the formulated samples of fixed dose combination of sitagliptin 
and metformin tablets (Janumet, Janumet XR) 50/1000 mg strength for 
determination of undesired (S)-enantiomer of sitagliptin. Each sample 
preparation was preceded by taking tablet powder equivalent to 150 mg 
of sitagliptin to the 50-ml flask to make the concentration of sitagliptin 3 
mg/ml. Added 2 ml of water before the addition of ethanol and sonicated 
for 30 min with intermittent shaking. Filtered samples were injected into 
HPLC with chromatographic conditions mentioned in section-
Chromatographic conditions. Before running the samples into HPLC, 
system suitability was tested by injecting racemic sitagliptin solution in 
isocratic mode with a run time 20 min. The same kind of sample 
preparation applied for the entire method validation study and placebo 
preparations. The typical chromatograms of system suitability solution 
and formulation sample are given in fig. 2C and 3B. 
  
 
Fig. 2: Typical chromatograms of (A) Blank as a diluent injection (B) Placebo solution containing metformin (C) System suitability 
solution containing racemic sitagliptin 
 
Method validation 
System suitability  
System Suitability tests are an integral part of chromatographic 
methods. They are used to verify the adequacy of the resolution and 
reproducibility of the chromatographic system for the analysis to be 
done. The parameters of these tests are column efficiency (number of 
theoretical plates), tailing of the chromatographic peak, peak 
resolution factor, and repeatability as % RSD of peak area for six 
injections. The typical chromatogram is given in fig. 2C. The results of 
system suitability tests for the proposed method are listed in table 1. 
Specificity 
Specificity is the ability of the method to assess unequivocally 
the analyte in the presence of matrix components. The specificity 
of the developed method was determined by the analysis of a 
solution containing (S)-enantiomer and its main related 
substances of sitagliptin and metformin. There were no 
interferences observed at retention time S-enantiomer of 
sitagliptin from diluent and with metformin matrix. The typical 
chromatograms are given in fig. 2A and 2B. 
Precision 
The repeatability of the method was examined by six-fold analysis of 
by spiking 4.5 µg/ml of (S)-enantiomer on formulation sample to 
obtain 3000 µg/ml solution of sitagliptin. The % RSD of retention 
times and peak areas for each enantiomer were well within 2.0%. 
The intermediate precision was also evaluated over 2 d by 
performing six successive preparations each day. The results are 
presented in table 2. 
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Fig. 3: Typical chromatograms of (A) Sample solution of combination tablets (Janumet) spiked with (S)-enantiomer at 0.3% level (B) 
Sample solution of combination tablets (Janumet) 
 
Table 1: System suitability parameters 
Compound  Rt Rs N T Area %RSD 
Sitagliptin 15.26±0.01 3.8±0.05 9586±75 1.11±0.01 21718±240 1.1 
(S)-enantiomer 13.80±0.03 -- 8672±110 1.18±0.01 22510±182 0.8 
*n= Number of experiments, each value expressed as mean±standard deviation (n=6), Rt: retention time, Rs: USP resolution, N: number of 
theoretical plates (USP tangent method), T: USP tailing, RSD: relative standard deviation  
 
Linearity of (S)-enantiomer of sitagliptin phosphate 
The linearity of detector response was assessed by preparing the 
calibration curve of sample solutions (S-enantiomer of sitagliptin) of 7 
concentration levels covering from 0.5µg/ml to 13.6µg/ml in ethanol 
diluent. A regression curve was obtained by plotting peak area versus 
respective concentration, using the least squares method. The slope 
and intercept of the calibration curve are exhibited in table 2. 
Limit of detection and limit of quantification of (S)-enantiomer 
of sitagliptin phosphate 
The limit of detection (LOD) is defined as the lowest concentration 
of analyte that can be clearly detected above the baseline signal, 
while the limit of quantification (LOQ) is defined as the lowest 
concentration of analyte that can be quantified with suitable 
precision and accuracy. The linearity performed above is used for 
the determination of the limit of quantification and detection. 
Residual standard deviation method was applied to predict the 
LOQ and LOD values using the following formula and the precision 
was established at these predicted levels. The results are 
presented in table 2. 
  
Where SD = residual standard deviation of response; S= slope of the 
calibration curve. 
 
Table 2: Validation results of the developed chiral LC method 
Validation parameter Results 
Repeatability (n=6, %RSD)  
Retention time (S-enantiomer)  0.2 
Peak area (S-enantiomer)  1.2 
Intermediate precision (n= 12, %RSD)  
Retention time (S-enantiomer)  0.3 
Peak area (S-enantiomer)  1.8 
LOD–LOQ (S-enantiomer)  
Limit of detection (µg/ml) 0.1551 
Limit of quantification (µg/ml) 0.5172 
Precision at LOQ (n=6, %RSD) 3.4 
Linearity (S-enantiomer)  
Calibration range (µg/ml) 0.5185 to 13.645 
Calibration points 7 
Correlation coefficient 0.9999 
Slope 5020.8 
Intercept -655.5 
*n= Number of experiments, RSD=Relative standard deviation 
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Recovery study of (S)-enantiomer of sitagliptin phosphate in 
the formulation sample 
Recovery experiments were conducted to determine the accuracy of 
the developed method for the quantification of (S)-sitagliptin in a 
combination product. The study was carried out in triplicate by 
spiking different levels of (S)-sitagliptin i.e. 0.017% (LOQ), 0.075%, 
0.15%, 0.23% and 0.3% of the target analyte concentration (3.0 
mg/ml of sitagliptin). The study results are given in table 3. 
 
Table 3: Recovery results of (S)-enantiomer in combination tablets 
Accuracy level a Amount recovered (µg) Amount added (µg) Recovery (%) RSD (%) n=3 
LOQ 51.64 49.11±1.59 95.1±3.1 3.2 
50% 229.49 223.98±3.95 97.6±1.7 1.8 
100% 458.98 447.05±5.55 97.4±1.2 1.2 
150% 688.47 677.46±9.03 98.4±1.3 1.3 
300% 1376.95 1352.16±15.78 98.2±1.1 1.2 
*n= Number of experiments, each value expressed as mean±standard deviation (n=3), a
 
Amount added to 100 ml of test preparation, RSD: relative 
standard deviation 
Robustness 
Robustness of the method was performed by deliberately changing 
the chromatographic conditions. The flow rate of the mobile phase 
was changed from 0.5 to 0.4 ml/min and 0.6 ml/min. The methanol 
strength of mobile phase-2 was varied by±5% while column 
temperature was varied by±5 °C. The solution of (S)-sitagliptin was 
spiked with the formulation sample was injected in each varied 
condition and the resolution between the isomers was checked. In 
all deliberately varied conditions, the resolution between the 
isomers was found to be well within the acceptance limit of 2% 
indicating the method robustness. 
Solution stability and mobile phase stability 
The variability in the estimation of (S)-sitagliptin in formulation 
sample was studied by keeping the solution at room temperature on 
bench top for 2 d. The content of (S)-enantiomer was checked for 12 
h interval up to the study period using the same mobile phase. The 
results are falling within±10% during the study. It is confirmed that 
standard solutions, sample solutions, and the mobile phase were 
stable up to 48 h for estimation of (S)-enantiomer. 
CONCLUSION 
A new chiral Reverse Phase-High Performance Liquid 
Chromatography (RP-HPLC) method was successfully developed for 
sitagliptin phosphate enantiomers in a fixed dose combination of 
sitagliptin phosphate and metformin hydrochloride tablets. This 
method is simple, accurate and has provided good linearity, 
precision, and reproducibility for determination of undesired (S)-
enantiomer of sitagliptin. The applicability of this method was tested 
by formulations of immediate release and extended release tablets 
of sitagliptin phosphate and metformin. The method can be used in 
quality control for monitoring of undesired (S)-enantiomer during 
manufacturing and for the quantitative determination of undesired 
(S)-enantiomer of sitagliptin in marketed formulations of sitagliptin 
phosphate with metformin and sitagliptin phosphate alone. 
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